T. Andrew Crockett
2021
In 2021, T. Andrew Crockett earned a total compensation of $2.3M as Chief Executive Officer at Carbylan Therapeutics, a 33% increase compared to previous year.
Compensation breakdown
| Bonus | $458,799 |
|---|---|
| Option Awards | $1,281,708 |
| Salary | $556,120 |
| Other | $11,400 |
| Total | $2,308,027 |
Crockett received $1.3M in option awards, accounting for 56% of the total pay in 2021.
Crockett also received $458.8K in bonus, $556.1K in salary and $11.4K in other compensation.
Rankings
In 2021, T. Andrew Crockett's compensation ranked 5,473rd out of 12,405 executives tracked by ExecPay. In other words, Crockett earned more than 55.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,473 out of 12,405 | 56th |
Division Manufacturing | 2,312 out of 5,494 | 58th |
Major group Chemicals And Allied Products | 1,004 out of 2,369 | 58th |
Industry group Drugs | 894 out of 2,090 | 57th |
Industry Pharmaceutical Preparations | 643 out of 1,537 | 58th |
Source: SEC filing on August 14, 2023.
Crockett's colleagues
We found two more compensation records of executives who worked with T. Andrew Crockett at Carbylan Therapeutics in 2021.